Reuters logo
BRIEF-Flex Pharma says US Phase 2 trial of FLX-787 in CMT patients to start this summer
June 2, 2017 / 12:31 PM / 4 months ago

BRIEF-Flex Pharma says US Phase 2 trial of FLX-787 in CMT patients to start this summer

June 2 (Reuters) - Flex Pharma Inc

* Flex Pharma’S Phase 2 trial with FLX-787 in charcot-marie-tooth endorsed by the inherited neuropathies consortium

* Flex Pharma Inc says US Phase 2 trial of FLX-787 in CMT patients to start this summer Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below